Virological characteristics of occult hepatitis B virus in a North American cohort of human immunodeficiency virus type 1-positive patients on dual active anti-HBV/HIV therapy

Journal of Clinical Virology

Volumn 60, Issue 4, 2014, Pages 347-353

  Coffin, Carla S ^a,b   Mulrooney Cousins, Patricia M ^c   Osiowy, Carla ^d   van der Meer, Frank ^b   Nishikawa, Sandra ^a,b   Michalak, Tomasz I ^c   van Marle, Guido ^b   Gill, M John ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Canada; Genotype; HIV; Lamivudine 3TC; Lymphoid cells; Occult HBV infection

Indexed keywords

CIRCULAR DNA; EMTRICITABINE; LAMIVUDINE; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; P PROTEIN, HEPATITIS B VIRUS; POL PROTEIN; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE SEQUENCE; GENOTYPE; HEPATITIS B VIRUS GENOTYPE C; HEPATITIS B VIRUS GENOTYPE D; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LYMPHOID CELL; MALE; MIDDLE AGED; NONHUMAN; NORTH AMERICAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; SEQUENCE ANALYSIS; VIRUS RESISTANCE; ASYMPTOMATIC DISEASE; BLOOD; DNA SEQUENCE; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HIV INFECTIONS; IMMUNOLOGY; MONONUCLEAR CELL; NORTH AMERICA; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ASYMPTOMATIC DISEASES; BASE SEQUENCE; DNA, VIRAL; FEMALE; GENE PRODUCTS, POL; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NORTH AMERICA; SEQUENCE ANALYSIS, DNA; VIRAL LOAD;

EID: 84903627174     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.04.021     Document Type: Article

References (57)

1. Thio C.L. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009, 49:S138-S145.
2. Raimondo G., Allain J.P., Brunetto M.R., Buendia M.A., Chen D.S., Colombo M., et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008, 49:652-657.
3. Raimondo G., Pollicino T., Cacciola I., Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007, 46:160-170.
4. Michalak T.I., Pasquinelli C., Guilhot S., Chisari F.V. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994, 93:230-239.
5. Penna A., Artini M., Cavalli A., Levrero M., Bertoletti A., Pilli M., et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996, 98:1185-1194.
6. Rehermann B., Ferrari C., Pasquinelli C., Chisari F.V. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996, 2:1104-1108.
7. Bréchot C., Thiers V., Kremsdorf D., Nalpas B., Pol S., Paterlini-Bréchot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?. Hepatology 2001, 34:194-203.
8. Samal J., Kandpal M., Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev 2012, 25:142-163.
9. Cacciola I., Pollicino T., Squadrito G., Cerenzia G., Orlando M.E., Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999, 341:22-26.
10. Shire N.J., Rouster S.D., Stanford S.D., Blackard J.T., Martin C.M., Fichtenbaum C.J., et al. The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2007, 44:309-314.
11. Núñez M., Ríos P., Pérez-Olmeda M., Soriano V. Lack of 'occult' hepatitis B virus infection in HIV-infected patients. AIDS 2002, 16:2099-2101.
12. Khamduang W., Ngo-Giang-Huong N., Gaudy-Graffin C., Jourdain G., Suwankornsakul W., Jarupanich T., et al. Prevalence, risk factors, and impact of isolated antibody to hepatitis B core antigen and occult hepatitis B virus infection in HIV-1-infected pregnant women. Clin Infect Dis 2013, 56:1704-1712.
13. Filippini P., Coppola N., Pisapia R., Scolastico C., Marrocco C., Zaccariello A., et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS 2006, 20:1253-1260.
14. Bell T.G., Makondo E., Martinson N.A., Kramvis A. Hepatitis B virus infection in human immunodeficiency virus infected southern African adults: occult or overt - that is the question. PLoS ONE 2012, 7:e45750.
15. Pogány K., Zaaijer H.L., Prins J.M., Wit F.W., Lange J.M., Beld M.G. Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients. AIDS Res Hum Retroviruses 2005, 21:922-926.
16. Bagaglio S., Porrino L., Lazzarin A., Morsica G. Molecular characterization of occult and overt hepatitis B (HBV) infection in an HIV-infected person with reactivation of HBV after antiretroviral treatment interruption. Infection 2010, 38:417-421.
17. Chadwick D., Stanley A., Sarfo S., Appiah L., Ankcorn M., Foster G., et al. Response to antiretroviral therapy in occult hepatitis B and HIV co-infection in West Africa. AIDS 2013, 27:139-141.
18. Manegold C., Hannoun C., Wywiol A., Dietrich M., Polywka S., Chiwakata C.B., et al. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2001, 32:144-148.
19. Cohen Stuart J.W., Velema M., Schuurman R., Boucher C.A., Hoepelman A.I. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol 2009, 81:441-445.
20. Bagaglio S., Bianchi G., Danise A., Porrino L., Uberti-Foppa C., Lazzarin A., et al. Longitudinal evaluation of occult hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption. Infection 2011, 39:121-126.
21. Wang H., Li Y., Zhang C., Han Y., Zhang X., Zhu T., et al. Immunological and virological responses to cART in HIV/HBV co-infected patients from a multicenter cohort. AIDS 2012, 26:1755-1763.
22. Eskild A., Magnus P., Petersen G., Sohlberg C., Jensen F., Kittelsen P., et al. Hepatitis B antibodies in HIV-infected homosexual men are associated with more rapid progression to AIDS. AIDS 1992, 6:571-574.
23. Pontisso P., Vidalino L., Quarta S., Gatta A. Biological and clinical implications of HBV infection in peripheral blood mononuclear cells. Autoimmun Rev 2008, 8:13-17.
24. Smith M.Z., Wightman F., Lewin S.R. HIV reservoirs and strategies for eradication. Curr HIV/AIDS Rep 2012, 9:5-15.
25. Norder H., Couroucé A.M., Coursaget P., Echevarria J.M., Lee S.D., Mushahwar I.K., et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004, 47:289-309.
26. Eberle J., Gurtler L. HIV types, groups, subtypes and recombinant forms: errors in replication, selection pressure and quasispecies. Intervirology 2012, 55:79-83.
27. Thio C.L. Virology and clinical sequelae of drug-resistant HBV in HIV-HBV-coinfected patients on highly active antiretroviral therapy. Antivir Ther 2010, 15:487-491.
28. Locarnini S.A., Yuen L. Molecular genesis of drug-resistant and vaccine-escape HBV mutants. Antivir Ther 2010, 15:451-461.
29. Sheldon J., Ramos B., Garcia-Samaniego J., Rios P., Bartholomeusz A., Romero M., et al. Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. J Acquir Immune Defic Syndr 2007, 46:279-282.
30. Martin C.M., Welge J.A., Shire N.J., Rouster S.D., Shata M.T., Sherman K.E., et al. Genomic variability associated with the presence of occult hepatitis B virus in HIV co-infected individuals. J Viral Hepat 2010, 17:588-597.
31. Coffin C.S., Mulrooney-Cousins P.M., van Marle G., Roberts J.P., Michalak T.I., Terrault N.A. Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy. Liver Transpl 2011, 17:955-962.
32. Coffin C.S., Mulrooney-Cousins P.M., Peters M.G., van Marle G., Roberts J.P., Michalak T.I., et al. Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy. J Viral Hepat 2011, 18:415-423.
33. Coffin C.S., Mulrooney-Cousins P.M., Lee S.S., Michalak T.I., Swain M.G. Profound suppression of chronic hepatitis C following superinfection with hepatitis B virus. Liver Int 2007, 27:722-726.
34. Osiowy C. Detection of HBsAg mutants. J Med Virol 2006, 78(Suppl. 1):S48-S51.
35. Ramezani A., Banifazl M., Mohraz M., Rasoolinejad M., Aghakhani A. Occult hepatitis B virus infection: a major concern in HIV-infected patients: occult HBV in HIV. Hepat Mon 2011, 11:7-10.
36. Lukhwareni A., Burnett R.J., Selabe S.G., Mzileni M.O., Mphahlele M.J. Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital. J Med Virol 2009, 81:406-412.
37. Raffa G., Maimone S., Cargnel A., Santantonio T., Antonucci G., Massari M. Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C. AIDS 2007, 21:2171-2175.
38. Witt M.D., Lewis R.J., Rieg G., Seaberg E.C., Rinaldo C.R., Thio C.L. Predictors of the isolated hepatitis B core antibody pattern in HIV-infected and -uninfected men in the multicenter AIDS cohort study. Clin Infect Dis 2013, 56:606-612.
39. Pardoe I.U., Michalak T.I. Detection of hepatitis B and woodchuck hepatitis viral DNA in plasma and mononuclear cells from heparinized blood by the polymerase chain reaction. J Virol Methods 1995, 51:277-288.
40. Roche B., Feray C., Gigou M., Roque-Afonso A.M., Arulnaden J.L., Delvart V., et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 2003, 38:86-95.
41. Noonan C.A., Yoffe B., Mansell P.W., Melnick J.L., Hollinger F.B. Extrachromosomal sequences of hepatitis B virus DNA in peripheral blood mononuclear cells of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A 1986, 83:5698-5702.
42. Pezzella M., Pezzella F., Rapicetta M., Morace G., Macchi B., Sorice F., et al. HBV and HIV expression in lymph nodes of HIV positive LAS patients: histology and in situ hybridization. Mol Cell Probes 1989, 3:125-132.
43. Bartolomé F.J., Moraleda G., Castillo I., Martinez M.G., Porres J.C., Carreño V. Presence of HBV-DNA in peripheral blood mononuclear cells from anti-HIV symptomless carriers. J Hepatol 1990, 10:186-190.
44. Cassini R., De Mitri M.S., Gibellini D., Urbinati L., Bagaglio S., Morsica G., et al. A novel stop codon mutation within the hepatitis B surface gene is detected in the liver but not in the peripheral blood mononuclear cells of HIV-infected individuals with occult HBV infection. J Viral Hepat 2013, 20:42-49.
45. Loustaud-Ratti V., Wagner A., Carrier P., Marczuk V., Chemin I., Lunel F., et al. Distribution of total DNA and cccDNA in serum and PBMCs may reflect the HBV immune status in HBsAg+ and HBsAg- patients coinfected or not with HIV or HCV. Clin Res Hepatol Gastroenterol 2013, 10.1016/j.clinre.2012.11.002.
46. Poles M.A., Boscardin W.J., Elliott J., Taing P., Fuerst M.M., McGowan I., et al. Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals. J Acquir Immune Defic Syndr 2006, 43:65-68.
47. Carman W.F. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 1997, 4(Suppl. 1):11-20.
48. Bloquel B., Jeulin H., Burty C., Letranchant L., Rabaud C., Venard V. Occult hepatitis B infection in patients infected with HIV: report of two cases of hepatitis B reactivation and prevalence in a hospital cohort. J Med Virol 2010, 82:206-212.
49. Costantini A., Marinelli K., Biagioni G., Monachetti A., Ferreri M.L., Butini L., et al. Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy. BMC Infect Dis 2011, 11:310.
50. Lada O., Benhamou Y., Poynard T., Thibault V. Coexistence of hepatitis B surface antigen (HBs Ag) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of "a" determinant variants. J Virol 2006, 80:2968-2975.
51. Ayres A., Locarnini S., Bartholomeusz A. HBV genotyping and analysis for unique mutations. Methods Mol Med 2004, 95:125-149.
52. Coffin C.S., Osiowy C., Myers R.P., Gill M.J. Virology and clinical sequelae of long-term antiviral therapy in a North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected patients. J Clin Virol 2013, 7(2):103-108.
53. Toan N.L., Song le H., Kremsner P.G., Duy D.N., Binh V.Q., Koeberlein B., et al. Impact of the hepatitis B virus genotype and genotype mixtures on the course of liver disease in Vietnam. Hepatology 2006, 43:1375-1384.
54. Hannoun C., Krogsgaard K., Horal P., Lindh M. Genotype mixtures of hepatitis B virus in patients treated with interferon. J Infect Dis 2002, 186:752-759.
55. Chauhan R., Kazim S.N., Kumar M., Bhattacharjee J., Krishnamoorthy N., Sarin S.K. Identification and characterization of genotype A and D recombinant hepatitis B virus from Indian chronic HBV isolates. World J Gastroenterol 2008, 14:6228-6236.
56. Andernach I.E., Jutavijittum P., Samountry B., Yousukh A., Thammavong T., Hübschen J.M., et al. A high variability of mixed infections and recent recombinations of hepatitis B virus in Laos. PLoS One 2012, 7:e30245.
57. Olinger C.M., Venard V., Njayou M., Oyefolu A.O., Maïga I., Kemp A.J., et al. Phylogenetic analysis of the precore/core gene of hepatitis B virus genotypes E and A in West Africa: new subtypes, mixed infections and recombinations. J Gen Virol 2006, 87:1163-1173.